OSW

Analyst Note: OSW (OneSpaWorld Holdings Limited)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

• Setup State: Actionable (Forming Coil)
• Conservative Entry: Not yet defined (requires a confirmed breakout close above the coil resistance).
• Breakout Level: Not yet defined (requires price to close above the coil resistance).
• Current Price: $27.53.
• Extension: Not applicable (price is within the coil structure, not extended above resistance).
• ATR Context: Current ATR is 3.0% (productive). This sits within the historical "sweet spot" (4–6% is ideal, but 3.0% indicates manageable volatility for position sizing without the elevated risk of >6% or the weakness of <2.5%).

2. Thesis Layer

• Thesis Classification: TACTICAL / Setup-Led.
• Macro Context: There is no named secular thesis attached to this setup as of 2026-06-13. The investment case is not driven by a broad macro narrative (e.g., "Global Wellness Boom" as a primary driver) but is strictly a function of the structural setup quality combined with the company's specific operational fundamentals.
• Judgment Criteria: The conviction must be derived entirely from the quality of the price structure (the forming coil) and the strength of the business fundamentals reported in the evidence block. No external macro thesis should be invented to bolster the case.

3. Business Overview

OneSpaWorld Holdings Limited (OSW) operates as a global provider of health, wellness, aesthetics, and fitness services, primarily situated aboard cruise ships and within premium destination resorts.

• Business Model: The company generates revenue through the operation of integrated wellness centers, offering services ranging from traditional spa therapies (body, salon, skin care) to advanced medi-spa services (IV therapy, acupuncture), fitness programs, and retail products (including exclusive brands like ELEMIS and Kérastase).
• Operational Footprint (as of Q1/Q2 2026):
• Ship Count: As of the end of Q1 2026, the company operated health and wellness centers on 208 ships, with an average ship count of 202 for the quarter. This represents growth from 199 ships and an average of 193 ships in Q1 2025.
• Medi-Spa Penetration: Medi-spa services were available on 155 ships at quarter end, up from 148 ships in Q1 2025. Management expects this to reach 157 ships by year-end 2026.
• New Deployments: During the quarter, the company introduced centers on two new ship builds: Norwegian Cruise Line's *Luna* and Disney Adventure. Management expects to introduce centers on 6 new ship-builds in 2026.
• Financial Performance (Management Expectations & Actuals):
• Q2 2026 Guidance: Management expects 10% growth in total revenues and adjusted EBITDA for the second quarter at the midpoint of guidance ranges (excluding exited/reorganized operations).
• Full Year 2026 Guidance: Total revenue expected in the range of $1.014 billion to $1.034 billion; Adjusted EBITDA expected in the range of $129 million to $139 million.
• 2025 Actuals: For the year ended Dec 31, 2025, the company reported Revenues of $961.0 million, Net Income of $71.6 million, and Adjusted EBITDA of $123.3 million.
• Productivity Drivers: Prebooked revenues grew 17%. These appointments generate 30% more guest spend than services booked on board. Higher-value services (medi-spa, IV therapy) continue to enhance onboard productivity.
• Capital Allocation: Capital expenditures are expected to be approximately 2% of revenues for each of the next two years, indicating a capital-light expansion model.

4. Archetype and Conviction Stack

• Archetype: Cyclical Recovery.
• Rationale: The company is demonstrating clear operational leverage and recovery in a cyclical industry (cruise travel). The data shows a rebound in ship counts (from 193 avg to 202 avg) and revenue growth (10% Q2 guidance), moving from the 2025 baseline of $961M toward the 2026 target of ~$1.02B. The "Cyclical Recovery" label fits the pattern of a business expanding its footprint (new ship builds) and increasing yield per guest (prebooked revenue growth) as the underlying demand cycle strengthens.
• Valuation Context:
• Forward consensus EPS for FY1 is $1.135 and FY2 is $1.297.
• At a current price of $27.53, the stock trades at approximately 24.2x FY1 EPS and 21.2x FY2 EPS.
• The "Mid" cap bucket classification suggests the market is pricing in a moderate level of certainty regarding the recovery, but the valuation is not at a deep value discount.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro thesis).
• Evidence Quality: High. The evidence block is robust, containing specific earnings transcript quotes (E1-E8) and SEC filings (E9-E16) with high confidence scores (0.65–0.7). The data is point-in-time and consistent.
• Setup Readiness: Partial. The setup is "Actionable" in the sense that the structure is defined, but it requires a breakout to become a "Confirmed" trade.
• Rerating Potential: Moderate. The combination of 10% growth guidance, expanding ship count, and high-margin prebooked revenue growth provides a fundamental basis for a multiple expansion if the breakout confirms.

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• Management guidance cuts for 2026 (e.g., missing the $1.014B revenue floor or $129M EBITDA floor) or a reduction in the expected ship count (e.g., missing the 157 medi-spa ships target).
• What Would Strengthen:
• A confirmed breakout close above the coil resistance level.
• Further acceleration in prebooked revenue growth (currently 17%) or an increase in the average ship count beyond 202.
• Confirmation of the 6 new ship-build introductions in 2026.
• Gaps in Evidence:
• Breakout Level: The specific resistance level required for the breakout is not explicitly priced.
• Debt/Cash Position: While EBITDA and Revenue are clear, specific details on the balance sheet (net debt, liquidity) are not detailed in the provided evidence, though the low CapEx (2% of revenue) suggests a healthy cash flow profile.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Management guidance for 10% Q2 growth and $1.014B-$1.034B full-year revenue; expansion of medi-spa footprint to 157 ships by year-end 2026; prebooked revenue growth of 17% driving 30% higher guest spend. Key risks: Failure of price to break out above the forming coil resistance; potential slowdown in cruise industry demand affecting ship count growth; execution risk on new ship-build introductions. Sizing hint: Position size should reflect the "forming" nature of the setup; smaller than a confirmed breakout trade, but larger than a pure speculative play due to strong fundamentals. Expected path: Price consolidates near current levels while management executes on the 6 new ship introductions and 10% growth guidance; a breakout occurs once the market prices in the confirmed Q2 results and full-year outlook. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or invalidation.